UK-14,304

UK-14,304 is a **potent and selective full agonist at alpha-2 adrenergic receptors**, used mainly as a pharmacological tool in research. It is a centrally active small molecule that, when administered systemically, demonstrates strong activity on alpha-2 adrenoceptors, including effects in the central nervous system. The compound is chemically described as 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline. It has been used in studies to characterize alpha-adrenoceptor subtypes and to investigate physiological processes dependent on alpha-2 adrenoceptor activity, such as the inhibition of neurotransmitter release, modulation of secretory processes, and neuropharmacological effects. UK-14,304 is not approved as a marketed pharmaceutical for clinical use but is widely utilized in research settings[2][10][16].

Other names

5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline